What does it all mean now that the Food and Drug Administration has issued a surprise decision to approve Sarepta Therapeutics’ Duchenne muscular dystrophy drug Vyondys 53, reversing its surprise decision to reject the drug in August?

Here are some thoughts and observations about the latest twist in the always twisty Sarepta story, including potential implications for Biogen and its controversial Alzheimer’s drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “Eventually, Sarepta will complete confirmatory clinical trials and collect the data necessary to prove or disprove that its exon-skipping drugs — Exondys 51, Vyondys 53, and casimersen — improve muscle function in Duchenne patients.”

    You have more faith in Sarepta than I do. I don’t think they will ever willingly do those trials. They will continue to push out exon skipping drugs as fast as they can to get as much money as they can without doing any confirmatory trials until gene therapy hits the market and they can scrap the whole model.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy